Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2018
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Access and Reimbursement | EU5 | 2018
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2018
Introduction: Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL …
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Treatment Sequencing | US | 2018
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2017
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma ( NHL ) therapy market over the…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 2 | 2017
Venclexta (Wave 2) is the second in a multiwave series designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL)…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Special Topics | CAR-T | Wave 1 | US | 2017
Market Outlook The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | First-Line Chronic Lymphocytic Leukemia | US/EU | 2017
Market Outlook: Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvica, Zydelig, and Gazyva/Gazyvaro, it remains largely an incurable disease…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 3 | 2017
Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Access and Reimbursement | EU5 | 2016
Recent and upcoming marketing authorizations and label expansions are increasing the therapy options for non-Hodgkin’s lymphoma (NHL). Despite a flourishing treatment armamentarium, tightening…
